4 June, 2021 - 00:14 By Tony Quested

CMR Surgical and Microsoft innovation could store health data for more than ten thousand years

Cambridge keyhole surgery robotics pioneer CMR Surgical has teamed with Microsoft to pilot a world first FutureTech innovation to store health data for centuries.

Through a space age initiative dubbed Project Silico, clinical data from Versius procedures was stored in a trial onto a small (75x75mm) proof of concept glass platter, which can be safely preserved for more than ten thousand years.

3 June, 2021 - 21:50

Buying a commercial property versus residential property: top 5 differences

You would imagine that buying a property is one process, regardless of its intended use and occupancy, writes Talia Jacobs, Solicitor with Birketts LLP.

The construction and design may also be fundamentally the same across residential and commercial premises; a commercial property could look like an endearing country cottage in the Cotswolds and a residential property could be mistaken for a block of offices in Shoreditch. 

3 June, 2021 - 11:44 By Tony Quested

Arecor market cap soars to c$100m after IPO

Arecor chairman Andy Richards

Cambridge biopharma business Arecor made a stunning bow on London’s AIM market today as its share price immediately grew wings.

At one stage in the early flurry of dealings the market cap had soared to $98.9 million.

The stock debuted at 226p but peaked at 250p at the height of activity: As exclusively predicted in Business Weekly mid-May, the UK business raised £20 million in an oversubscribed round.

3 June, 2021 - 00:19 By Tony Quested

Takeda helps Cambridge startup out of stealth with £9.1m seed funding

Cambridge startup Transine Therapeutics has emerged from stealth with £9.1 million seed funding – co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund  (DDF) – to advance a novel class of therapeutic RNA to combat hard to treat diseases.

The funding will enable Transine to further develop its proprietary platform towards building a pipeline of novel mRNA-targeted therapeutics initially focused on the Central Nervous System and Ophthalmology applications.

28 May, 2021 - 11:19 By Tony Quested

Canadians pay £45m for Cambridge Science Park asset in swoop on Golden Triangle

Canadian power player Oxford Properties Group, a leading global real estate investor, asset manager and business builder, has extended its global life sciences platform with the acquisition of 310 Cambridge Science Park – its first investment in the sector in Europe. And it is pledging further millions to buying assets in the Cambridge-Oxford-London ‘Golden Triangle.’

Since its first investment in the sector in 2017, building a substantial and dedicated life sciences business has been one of the Toronto group’s highest conviction investment strategies. 

27 May, 2021 - 20:55

Time to sell? Time for an Employee Ownership Trust?

An Employee Ownership Trust (EOT) is a form of employee ownership where a Trust acquires a majority stake in a business on behalf of all employees, writes David Scrivener – Corporate Finance partner, Ensors Chartered Accountants. 

Over recent years the EOT has become a much more widely used tool to sell a business (tax efficiently) and has also become a valuable way to engage the workforce.

26 May, 2021 - 20:10 By Tony Quested

Planning inspectors back Stansted’s expansion to 43m passengers a year

Stansted Airport has been cleared for take-off with plans to expand capacity to 43 million passengers a year following a thumbs-up from the Planning Inspectorate.

Stansted winning the legal battle means a huge financial backlash for Uttlesford District Council taxpayers running into several hundreds of thousands.

26 May, 2021 - 16:16

Are you ready for life after your business?

Selling your business is an emotional time and usually a one-off life event. Rarely are you given a second chance. So the following should be considered if you are a business owner or entrepreneur planning to sell your business, writes Ben Hewitt of insurance specialist, Alan Boswell Group.

25 May, 2021 - 21:33 By Tony Quested

Eliem Therapeutics Series B takes fundraising haul to $140 million

Cambridge UK and Seattle biotech company Eliem Therapeutics has raised $60 million Series B financing – taking its haul to date to $140m.

Eliem is developing novel therapies for neuronal excitability disorders. The technology addresses unmet needs in disorders of the peripheral and central nervous systems. 

The latest financing round was led by Intermediate Capital Group and RA Capital Management and included participation from Access Biotechnology, Samlyn Capital, Acorn Bioventures and LifeArc. 

20 May, 2021 - 20:35 By Tony Quested

Arm on top of the world: 70 million chips a day shipped

Arm's silicon partners shipped a record 7.3 billion Arm-based chips in the last calendar quarter of 2020, equating to more than 900 chips per second and 70 million chips a day. 

That is 22 per cent up year-on-year, the Cambridge technology innovator revealed. The growth rate suggests that 100 per cent of the world’s shared data will soon be processed on Arm.

Arm partners shipped 25 billion Arm-based chips in 2020 (up 13 per cent year-on-year), bringing the total deployment of Arm-based chips to-date to more than 190 billion.

Pages